Ranolazine-d8
| Product Name | Ranolazine-d8 |
|---|---|
| Alternate Names | Ranolazine Stable Isotopes, Stable Isotopes of Ranolazine |
| CAT No. | CS-O-10474 |
| CAS No. | 1092804-88-0 |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 435.59 g/mol |
| Mol. For. | C₂₄H₂₅D₈N₃O₄ |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Ranolazine |
| Purity | 95% |
| Smileys | OC(CN1C([2H])([2H])C([2H])([2H])N(CC(NC(C(C)=CC=C2)=C2C)=O)C([2H])([2H])C1([2H])[2H])COC(C=CC=C3)=C3OC |
| Canonical Smiles | CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O |
| InchIKey | XKLMZUWKNUAPSZ-FUEQIQQISA-N |
| Inchl | InChI=1S/C24H33N3O4/c1-18-7-6-8-19(2)24(18)25-23(29)16-27-13-11-26(12-14-27)15-20(28)17-31-22-10-5-4-9-21(22)30-3/h4-10,20,28H,11-17H2,1-3H3,(H,25,29)/i11D2,12D2,13D2,14D2 |
| IUPAC | N-(2,6-dimethylphenyl)-2-[2,2,3,3,5,5,6,6-octadeuterio-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Ranolazine-d8 is a deuterated analog of ranolazine, a medication used for the treatment of chronic angina pectoris. It is a selective inhibitor of the late sodium current in cardiomyocytes, which reduces intracellular calcium overload and improves myocardial relaxation. Ranolazine-d8 can be used for pharmacokinetic studies and quantitative analysis in biological samples.
Chemically, ranolazine-d8 is a white to off-white crystalline powder with a molecular weight of 415.6 g/mol. It is soluble in water and ethanol, and has a melting point of 166-168°C. The deuterium substitution at the eight position of the ranolazine molecule can be detected by mass spectrometry and nuclear magnetic resonance spectroscopy, which allows for precise identification and quantification.
Ranolazine-d8 is typically administered orally, with a recommended starting dose of 500 mg twice daily. It is metabolized by the liver and excreted in the urine, with a half-life of approximately 7 hours. Due to its potential interactions with other medications and conditions, it is important to consult with a healthcare provider before taking ranolazine-d8.
Overall, ranolazine-d8 is a useful tool for researchers studying the pharmacokinetics and effects of ranolazine in the body. Its deuterium substitution allows for sensitive and accurate analysis, which can aid in the development of new treatments for angina and other cardiovascular conditions.
Get an Instant Quote
Related Compounds
Ranolazine D3 | Desmethoxy Ranolazine-d5 | Ranolazine D8 Hydrochloride | Ranolazine D3 HCl |